Ondansetron

This page contains recent news articles, when available, and an overview of Ondansetron but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.

Overview:

Ondansetron (when available)

Pharmacology and use:
Ondansetron is an antinauseant and antiemetic agent indicated for the prevention of nausea and vomiting associated with moderately-emetogenic cancer chemotherapy and for the prevention of postoperative nausea and vomiting. Ondansetron is a highly specific and selective serotonin 5-HT₃ receptor antagonist, not shown to have activity at other known serotonin receptors and with low affinity for dopamine receptors. For treatment of chemotherapy-induced nausea and vomiting

Mechanism Of Action:
Ondansetron is a selective serotonin 5-HT₃ receptor antagonist. The serotonin 5-HT₃ receptors are located on the nerve terminals of the vagus in the periphery and centrally in the chemoreceptor trigger zone of the area postrema. It is thought that chemotherapeutic agents produce nausea and vomiting by releasing serotonin from the enterochromaffin cells of the small intestine, and that the released serotonin then activates 5-HT₃ receptors located on vagal efferents to initiate the vomiting reflex. Therefore Ondansetron works by blocking the reception of serotonin at these 5-HT₃ receptors.

News Articles on Ondansetron

Eurand Reports Recent Developments and Second Quarter 2008 ...  -  07 Aug 2008
EUR-1025 -- Once-Daily Formulation of Ondansetron * In February 2008, Eurand announced positive results of a pilot pharmacokinetic study demonstrating MarketWatch

Par Pharmaceutical Reports Second Quarter 2008 Results  -  07 Aug 2008
...cabergoline, and a decline in many of the Company's other products due to pricing pressures as well as lower royalties driven from ondansetron ODT. MarketWatch

Barr Pharmaceuticals, Inc. Q2 2008 Earnings Call Transcript  -  07 Aug 2008
Partially offsetting these higher sales were lower sales of Ondansetron due to lower volume and pricing, as well as lower sales of Desmopressin and Warfarin Seeking Alpha,

NovaDel Reports Financial Results for Second Quarter 2008  -  07 Aug 2008
...the Company entered into an agreement with BioAlliance Pharma SA whereby BioAlliance acquired the European rights for NovaDel's ondansetron oral spray, Genetic Engineering News (press release),

BioAlliance Pharma Complements Its Portfolio with a European ...  -  Aug 3, 2008
Ondansetron thin film formulation is a new oral formulation for the prevention of chemotherapy-induced nausea and vomiting, prevention of nausea and WELT ONLINE,

BioAlliance Pharma obtains European license for ondansetron ...  -  Aug 3, 2008
Ondansetron thin film formulation is a new oral formulation for the prevention of chemotherapy-induced nausea and vomiting, prevention of nausea and RTT News,

BioAlliance Pharma Publishes Its Q2 2008 Turnover  -  Jul 21, 2008
In May 2008, the company announced the acquisition of the European marketing rights for Ondansetron OS (Oral Spray) from the company NovaDel Pharma Inc. Euronext (persbericht),

MonoSol Rx Completes Thin Film Escitalopram Oxalate Pilot Product ...  -  Aug 4, 2008
...including the recently announced licensing of our thin film formulation of ondansetron, an anti-emetic therapy, to Strativa Pharmaceuticals, Biloxi Sun Herald,

Advice for Pet Owners  -  Jul 30, 2008
Ask your veterinarian about using antiemetics such as metoclopramide, ondansetron, and/or maropitant. Thanks! Dumfries, Va. Washington Post,

KU team’s research on drug for schizophrenia makes headway  -  Jul 21, 2008
However, long term use of Buspirone and Ondansetron retain its effectiveness to produce anxiolytics effects. Our findings proposed that novel compounds can The News - International,

Industry Insider  -  Aug 6, 2008
...use of multi-source products (eg carboplatin, cisplatin, doxorubicin, granisetron, irinotecan, ondansetron, paclitaxel, pamidronate, vinorelbine, etc. HONIonline,

BUYINS.NET: LTS, BJGP, BUSE, EWBC, MBLX, MDVN Have Been On BUYINS ...  -  Jul 31, 2008
The company's developing products include Ferriprox for iron overload; Flashtab Ondansetron for nausea and vomiting; Clindesse for bacterial vaginosis; Trading Markets (press release),

BioAlliance Pharma Launches Loramyc® in the United Kingdom ...  -  Jul 10, 2008
In May 2008, the company expanded its product portfolio via acquisition of the European commercial rights to ondansetron Oral Spray (OS) from NovaDel Pharma Business Wire (press release),

Transcept Pharmaceuticals to Present at the BMO Capital Markets ...  -  Jul 23, 2008
Transcept is also developing TO-2060, a novel, fixed-dose combination of olanzapine and ondansetron for the treatment of dopamine associated psychiatric PharmaLive.com (press release),

Transcept Pharmaceuticals to Present at the BMO Capital Markets ...  -  Jul 23, 2008
Transcept is also developing TO-2060, a novel, fixed-dose combination of olanzapine and ondansetron for the treatment of dopamine associated psychiatric PR Newswire (press release),

BioAlliance gains marketing rights to oral nausea drug  -  Aug 4, 2008
French drugmaker BioAlliance Pharma secured a deal with APR Applied Pharma Research and its partner Labtec for the European marketing rights of ondansetron SmartBrief,

AMDL Acquires China-Based Drug Distributor  -  Jul 9, 2008
SZP will distribute additional AMDL pharmaceutical products including GoodNak, Levofloxicin and Ondansetron. SZP currently employs approximately 80 in-house Seeking Alpha,

04/08/08 07:34 BioAlliance Pharma : enrichit son portefeuille avec ...  -  Aug 3, 2008
Et d'enrichir notre portefeuille grâce à deux systèmes de délivrance uniques et complémentaires : Ondansetron oral spray, de NovaDel, et le film fin oral, Challenges,

국제약품, 새로운 제형 항구토제 �?��?공급  -  Jul 14, 2008
...국제약품�?� 스위스�?� �?신�?�?� 개량신약 전문 개발업체�?� APR사(Applied Pharma Research SA)와 항암요법시 발�?하는 구역구토를 치료하는 항구토제 'Ondansetron 메디파나뉴스,

BioAlliance Pharma Suspends the  -  Jul 15, 2008
In May 2008, the company expanded its product portfolio via acquisition of the European commercial rights to ondansetron Oral Spray (OS) from NovaDel Pharma Ad-Hoc-News (Pressemitteilung),

혈액투�? 환�?用 ‘레나젤정’, 복막투�?�?�?� 가능  -  Jul 30, 2008
...나제아주사액) *dolasetron mesylate 제제(품명：안제메트정·주사) *granisetron HCl 제제(품명카�?�트릴정·카�?�트릴주) *ondansetron hydrochloride dihydrate 메디�?�뉴스,

Le gastroenteriti pediatriche  -  Jul 22, 2008
...extrapiramidale) oppure all'ondansetron (che pare essere gravato da una minor incidenza di effetti collaterali, però potrebbe aggravare la diarrea). Pillole.org,

BioAlliance Pharma présente son chiffre d'affaires du deuxième ...  -  Jul 21, 2008
...développement clinique du produit aux Etats-Unis et a initié ce trimestre les études de bioéquivalence chez l'homme vis-à-vis du comprimé d'ondansetron. Euronext (persbericht),

Complicaciones gastrointestinales de la diabetes  -  Jul 8, 2008
Los antieméticos como la prometazina y el ondansetron pueden aliviar la náusea persistente. La estimulación eléctrica del estómago ha sido aprobada para el Intramed.net (Suscripción),

Strativa gets commercialization rights to MonoSol's thin film ...  -  Jun 17, 2008
MonoSol's ondansetron thin film formulation is a new oral formulation in development for the prevention of chemotherapy-induced, radiotherapy-related, RTT News,

Strativa Pharmaceuticals acquires commercialisation rights to ...  -  Jun 18, 2008
Reportedly, Ondansetron thin film formulation is a new oral formulation in development for the prevention of chemotherapy-induced nausea and vomiting, Trading Markets (press release),

AMDL's Jade Pharma signs LoI with Sichuan ZhiTong Pharma of China ...  -  Jul 1, 2008
...agreement where the Sichuan ZhiTong would distribute additional AMDL pharmaceutical products including GoodNak, Levofloxicin and Ondansetron. RTT News,

Strativa licenses MonoSols delivery technology  -  Jun 24, 2008
Ondansetron is a therapeutic used in the prevention of nausea and vomiting induced by chemotherapy, radiotherapy and operations. In-PharmaTechnologist.com,

Transcept Pharmaceuticals Appoints Key Senior Executives  -  Jul 2, 2008
Transcept is also developing TO-2060, a novel, fixed-dose combination of olanzapine and ondansetron for the treatment of dopamine associated psychiatric Earthtimes (press release),

Industry Insider  -  Jul 2, 2008
...use of multi-source products (eg carboplatin, cisplatin, doxorubicin, granisetron, irinotecan, ondansetron, paclitaxel, pamidronate, vinorelbine, etc. HONIonline,

AMDL to buy Chinese distributor  -  Jul 2, 2008
...distribute numerous AMDL products locally, include the anti-aging skin treatment GoodNak, the antibiotic Levofloxacin and the anti-emetic Ondansetron. In-PharmaTechnologist.com,

BioAlliance Pharma Extends Its Loramyc(TM) License To China ...  -  Jun 22, 2008
In May 2008, the company expanded its product portfolio via acquisition of the European commercial rights to ondansetron Oral Spray (OS) from NovaDel Pharma WELT ONLINE,

AMDL Signs Letter of Intent to Purchase China-Based Pharmaceutical ...  -  Jul 1, 2008
...enter into a distribution agreement where SZP will distribute additional AMDL pharmaceutical products including GoodNak, Levofloxicin and Ondansetron. FOXBusiness

AMDL Announces Guidance for FY2008  -  Jun 23, 2008
...products that include Ondansetron Hydrochloride, Domperidone tablets, Levofloxacin injectables, Diavitamin tablets and Goodnak injectible solutions. PR Newswire (press release),

Transcept Pharmaceuticals to Present at the Jefferies 2nd Annual ...  -  Jun 18, 2008
Transcept is also developing TO-2060, a novel, fixed-dose combination of olanzapine and ondansetron for the treatment of dopamine associated psychiatric PR Newswire (press release),

Paul Rousseau, MD  -  Jun 17, 2008
But irrespective, I was introduced to some new friends: cyclophosphamide, ondansetron, prednisone, alendronate, omeprazole, furosemide, and others whose Journal of American Medical Association (subscription),

Gastrointestinal Complications of Diabetes  -  Jun 17, 2008
...other drugs.7 Antiemetics, such as promethazine (Phenergan) and ondansetron (Zofran), may be prescribed for symptomatic relief of persistent nausea. RedOrbit,

Intermezzo(R) 3.5 mg Achieves Greater Early Bioavailability Than ...  -  Jun 11, 2008
Transcept is also developing TO-2060, a novel, fixed-dose combination of olanzapine and ondansetron for the treatment of dopamine associated psychiatric Earthtimes (press release),

Transcept Pharmaceuticals Announces Intent to Submit New Drug ...  -  Jun 4, 2008
Transcept is also developing TO-2060, a novel, fixed-dose combination of olanzapine and ondansetron for the treatment of dopamine associated psychiatric PR Newswire (press release),

BUYINS.NET: JEF, TRX, TSL, RCH, AMWD, BJGP Have Been Added To ...  -  Jun 5, 2008
The company's developing products include Ferriprox for iron overload; Flashtab Ondansetron for nausea and vomiting; Clindesse for bacterial vaginosis; Trading Markets (press release),

KV Pharmaceutical Company Reports Fiscal 2008 Results  -  Jun 16, 2008
Product Launches -- Ondansetron Orally Disintegrating Tablets 4 mg and 8 mg (Zofran ODT(R) marketed by GlaxoSmithKline) indicated for the prevention of Earthtimes (press release),

Market Report -- In Play (PRX)  -  Jun 17, 2008
Par Pharmaceutical acquires commercialization rights to thin film formulation of ondansetron from MonoSol Rx; total milestone payments could be as high as MSN Money

Stabilised Compositions Comprising Probiotics  -  Jun 19, 2008
...laxatives, octreotide, cisapride, anticholinergies, calcium channel blockers, 5HT3-antagonists such as ondansetron and peptides such as insulin. FLEXNEWS,

Brand Names/Synonyms:
Ondansetron is also known by the following brand names and/or synonymsZophren; Zofran; Zudan; Zofran ODT

Drug Category:
Ondansetron is categorized under the following by the FDA: Anti-anxiety Agents; Antipsychotics; Antipruritics; Antiemetics; Serotonin Antagonists; ATC:A04AA01

Dosage Forms:
TABLET; LIQUID

Absorption:
Ondansetron is well absorbed after oral administration and undergoes limited first-pass metabolism.

Interactions:
Interactions for Ondansetron: Ondansetron does not itself appear to induce or inhibit the cytochrome P-450 drug-metabolizing enzyme system of the liver. Because ondansetron is metabolized by hepatic cytochrome P-450 drug-metabolizing enzymes (CYP3A4, CYP2D6, CYP1A2), inducers or inhibitors of these enzymes may change the clearance and, hence, the half-life of ondansetron. On the basis of limited available data, no dosage adjustment is recommended for patients on these drugs. Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3 Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5 Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron. In humans, carmustine, etoposide, and cisplatin do not affect the pharmacokinetics of ondansetron. In a crossover study in 76 pediatric patients, I.V. ondansetron did not increase blood levels of high-dose methotrexate.

Chemical IUPAC Name:
9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-1,2,3,9-tetrahydrocarbazol-4-one

:

Web health.mongabay.com

Disclaimer:

Contact a physician with regard to health concerns. Email requests for further health information will be discarded.

The materials contained on this Web site are for informational purposes only and do not constitute health or medical advice. Use of information on this site does not create or constitute any kind of agreement or contract between you and the owners or users of this site, the owners of the servers upon which it is housed, or anyone else who is in any way connected with this site.

Many links on health.mongabay.com lead to other sites. health.mongabay.com does not sponsor, endorse or otherwise approve of the materials appearing in such sites. Nor is health.mongabay.com responsible for dead or misdirected links.